14 Results for "

liver lysosomes

" in MedChemExpress (MCE) Product Catalog:
Products (14)

14 Results for "liver lysosomes" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-A0077
CAS No.: 58-39-9
Perphenazine is an orally active dopamine receptor and histamine-1 receptor antagonist, with Ki values of 0.56 nM (D2), 0.43 nM (D3), 6 nM (5-HT2A), respectively. Perphenazine also binds to Alpha-1A adrenergic receptor. Perphenazine inhibits cancer cell proliferation, and induces apoptosis. Perphenazine can be used in the research of mental disease, cancer, inflammation .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W032848
CAS No.: 24237-54-5
Synonyms: Y-3642
Target:  

COX

Research Areas:  

Inflammation/Immunology

Tinoridine (Y-3642) is an orally active non-steroidal anti-inflammatory agent with potent antiperoxidative ability and radical scavenger activity. Tinoridine acts function by inhibiting COX enzyme, involves in hepatotoxicity inhibition. .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-114986
CAS No.: 67786-53-2
Purity:  ≥99.0%
Synonyms: 6-keto-Prostaglandin E1
Target:  

β-glucuronidase

Research Areas:  

Cardiovascular Disease

6-Keto-PGE1 (6-keto-Prostaglandin E1) is a biologically active derivative of PGE1. 6-Keto-PGE1 inhibits adenosine diphosphate-induced platelet aggregation. 6-Keto-PGE1 reduces cardiac afterload, decreases the accumulation of plasma myocardial depressant factor (MDF), lowers arterial blood pressure, dilates vascular beds, inhibits the vasoconstrictive response of vascular smooth muscle, and increases pulmonary compliance. 6-Keto-PGE1 directly stabilizes isolated cat liver lysosomes and significantly reduces the release of β-glucuronidase and cathepsin D. 6-Keto-PGE1 prolongs the survival time of traumatized rats and exerts protective effects through hemodynamic and cytoprotective actions. 6-Keto-PGE1 reduces central airway resistance. 6-Keto-PGE1 can be used in studies related to traumatic shock .
loading...
    loading...
Cat. No.: HY-148118A
CAS No.: 1159408-65-7
Purity:  98.09%
Target:  

LYTACs

Research Areas:  

Cancer

Tri-GalNAc(OAc)3 TFA is a trivalent N-acetylgalactosamine (GalNAc) derivative that can be used to synthesize GalNAc-LYTAC. Tri-GalNAc is a specific ligand targeting the asialoglycoprotein receptor (ASGPR), mediating the endocytosis and transport of cell surface proteins (such as EGFR, HER2) to lysosomes for degradation by lysosomal targeting chimeras (LYTACs). Tri-GalNAc significantly reduces the level of target proteins and inhibits downstream signaling pathways (such as EGFR-mediated Akt and MAPK signals). Tri-GalNAc(OAc)3 TFA can be used for hepatocyte targeting studies, and can degrade carcinogenic membrane proteins and inhibit tumor cell proliferation in liver cancer cell models .
loading...
    loading...
Cat. No.: HY-179737
CAS No.: 3062599-51-0
Target:  

LYTACs

Research Areas:  

Metabolic Disease

ASGPR ligand-2 (Compound 366) is an asialoglycoprotein receptor (ASGPR) binder. ASGPR ligand-2 can be coupled with recognition elements of target proteins (such as antibodies or antigen-binding fragments), and through the endocytosis mediated by ASGPR, the target protein is delivered to the lysosomes of liver cells, promoting the degradation of the target protein. ASGPR ligand-2 can be used for the research of metabolic disease .
loading...
    loading...
Cat. No.: HY-A0077A
CAS No.: 2015-28-3
Perphenazine dihydrochloride is an orally active dopamine receptor and histamine-1 receptor antagonist, with Ki values of 0.56 nM (D2), 0.43 nM (D3), 6 nM (5-HT2A), respectively. Perphenazine dihydrochloride also binds to Alpha-1A adrenergic receptor. Perphenazine dihydrochloride inhibits cancer cell proliferation, and induces apoptosis. Perphenazine dihydrochloride can be used in the research of mental disease, cancer, inflammation .
loading...
    loading...
Cat. No.: HY-137227
CAS No.: 71154-83-1
Synonyms: 15(R)-Pinanethromboxane A2
Research Areas:  

Cardiovascular Disease

15(R)-PTA2 (15(R)-Pinanethromboxane A2) is an antithrombotic agent that inhibits platelet aggregation. 15(R)-PTA2 inhibits stable prostaglandin endoperoxide analog-induced constriction of feline coronary arteries and stabilizes hepatic lysosomes. 15(R)-PTA2 also inhibits thromboxane synthase but has no effect on prostacyclin synthase .
loading...
    loading...
Cat. No.: HY-173150
CAS No.: 106928-29-4
Hapalindole Q (Compound (+)-1) is an autophagy (Autophagy) inhibitor targeting YAP1. Hapalindole Q binds to the Hippo pathway transcription factor YAP1 with a Kd of 9.13 μM and induces its degradation via the chaperone-mediated autophagy (CMA) pathway. This process inhibits Rab7-mediated fusion of autophagosomes and lysosomes, thereby reducing overall autophagy levels without affecting lysosomal function. Hapalindole Q holds promise for research in cancer (e.g., liver cancer, breast cancer, etc.) .
loading...
    loading...
Cat. No.: HY-A0077R
CAS No.: 58-39-9
Perphenazine (Standard) is the analytical standard of Perphenazine. This product is intended for research and analytical applications. Perphenazine is an orally active dopamine receptor and histamine-1 receptor antagonist, with Ki values of 0.56 nM (D2), 0.43 nM (D3), 6 nM (5-HT2A), respectively. Perphenazine also binds to Alpha-1A adrenergic receptor. Perphenazine inhibits cancer cell proliferation, and induces apoptosis. Perphenazine can be used in the research of mental disease, cancer, inflammation .
loading...
    loading...
Cat. No.: HY-184926
PEG9MA10-PAB10-GalMA10 is a CD147 LYTAC degrader. PEG9MA10-PAB10-GalMA10 binds to the asialoglycoprotein receptor (ASGPR) via its galactose methacrylate domain, mediating its uptake by hepatoma cells. PEG9MA10-PAB10-GalMA10 induces lysosome-dependent degradation of CD147, resulting in concurrent loss of associated MCT1 and MCT4. PEG9MA10-PAB10-GalMA10 reduces extracellular lactate levels, increases intracellular lactate accumulation, inhibits glycolytic activity, and enhances mitochondrial respiratory capacity. PEG9MA10-PAB10-GalMA10 decreases the secretion of MMP-2 and MMP-9, and upregulates the expression of E-cadherin. PEG9MA10-PAB10-GalMA10 exhibits anti-tumor efficacy in hepatoma models. PEG9MA10-PAB10-GalMA10 can be used for research on liver cancer (hepatocellular carcinoma) .
loading...
    loading...
Cat. No.: HY-D3087
CAS No.: 1966158-27-9
Target:  

Fluorescent Dye

Research Areas:  

Cancer

Lyso-OC is a two-photon fluorescent probe that enables real-time monitoring of autophagy through ultrasensitive detection of lysosomal polarity changes. Lyso-OC possesses a coumarin (HY-N0709) solvatochromic group and a morpholine lysosome-targeting group, allowing selective lysosomal localization in living cells. Lyso-OC emits strong fluorescence in low-polarity lysosomes, whereas in high-polarity autolysosomes formed during autophagy, its fluorescence intensity decreases and the emission peak shifts by approximately 30 nm. For two-photon detection, the excitation/emission wavelengths of Lyso-OC are 760/490-550 nm, and its one-photon excitation wavelength is 375 nm. Lyso-OC can be used in cancer-related research .
loading...
    loading...
Cat. No.: HY-D3025
Synonyms: HSA-FITC
Target:  

Fluorescent Dye

Research Areas:  

Others

Human Serum Albumin-FITC (HSA-FITC) is a green fluorescent probe prepared by covalent conjugation of FITC with human serum albumin (HSA), with excitation/emission wavelengths of 488/505-550 nm. Human Serum Albumin-FITC (HSA-FITC) can be used to track nanotube conjugates taken up via caveolae-mediated endocytosis initiated by Gp60 receptor binding, and can also non-covalently adsorb to oxidized multi-walled carbon nanotubes. Human Serum Albumin-FITC (HSA-FITC) is widely applied in macrophage imaging, scavenger receptor targeting, and hepatoma cell imaging .
loading...
    loading...
Cat. No.: HY-184158
HATC is a HIF-1α AUTAC degrader. HATC links HIF-1α to LC3 to form a ternary complex that undergoes degradation via the autophagy-lysosome fusion pathway. HATC induces dose-dependent HIF-1α degradation in multiple cell types. HATC reduces visceral fat accumulation, hepatic lipid deposition, senescent cell aggregation, and bone loss; alleviates age-related intervertebral disc degeneration, liver dysfunction, kyphosis, and alveolar dilation; decreases circulating lactic acid levels; improves physical performance; and reverses age-related changes in granulocyte proportions. HATC extends median and maximum lifespan, reduces transcriptomic age, and causes no obvious persistent toxicity. HATC can be used in the research of age-related diseases (pink: LC3 ligand (HY-50759); blue: HIF-1α ligand (HY-P10426); Linker: (HY-W008264)) .
loading...
    loading...
Cat. No.: HY-P11779A
Ac-RKAA-PABC-MMAE TFA is a Drug-Linker Conjugates for ADC. Ac-RKAA-PABC-MMAE TFA consists of the ADC Cytotoxin MMAE (HY-15162) and a linker. Ac-RKAA-PABC-MMAE TFA can be used for synthesis of ADCs .
loading...
    loading...
  • 1